ADHD

The company has announced plans to submit the NDA in the first half of 2025.

Here are highlights from the first day of this year’s APA Annual Meeting.

This 2024 APA Annual Meeting poster covered a literature review on the relationship between stimulant use and failure to thrive in pediatric patients with ADHD.

A look at 3 different psychiatric perspectives for successfully diagnosing ADHD in previously undiagnosed adults.

What are the connections between what we eat and disorders such as anxiety and depression?

What is new in research on opioid use disorder?

Tris Pharma has formed the organization along with a licensing agreement with Braingaze for development, distribution of the technology.

“The heart of the matter.” Researchers investigated the risk of cardiovascular disease associated with long-term ADHD medication use.

From mild cognitive impairment and serotonin system degeneration to an update on pimavanserin for negative symptoms of schizophrenia, here are highlights from the week in Psychiatric Times.

What is new in research on child and adolescent psychiatry?

Here’s why ADHD is a diagnosis of exclusion.

What is new in research on ADHD?

The experts weighed in on a wide variety of psychiatric issues for the February 2024 issue of Psychiatric Times.

From psychotherapy vs pharmacotherapy for depression in heart failure to an update on the 2024 medication pipeline for antidepressants and ADHD treatments, here are highlights from the week in Psychiatric Times.

Check out this broad range of innovative medications in development with the goal of providing psychiatric clinicians with novel treatments in the quest to decrease patient suffering and improve function and quality of life.

From noninvasive brain stimulation for substance use disorders to updates from APSARD 2024, here are highlights from the week in Psychiatric Times.

Check out these APSARD 2024 updates from Greg Mattingly, MD, president of the American Professional Society for ADHD and Related Disorders.

This APSARD 2024 conference poster finds that individuals with ADHD have distinct motivations and patterns of substance use.

The results were shared in a poster presentation at the 2024 APSARD Annual Meeting.

APSARD tackles the first US adult ADHD treatment guidelines.

Ann Childress, MD, the current president of APSARD, invites you to attend this year's conference!

In an exclusive interview, APSARD President Elect Greg Mattingly, MD, tells Psychiatric Times readers what they can expect at this year's meeting.

Here are highlights from some of the year’s top features in Psychiatric Times from throughout 2023.

Reviewing a year of CMEs in Psychiatric Times®

From a new look at the famous STAR*D study to updates from the National Academy of Sciences Conference on Adult ADHD, here are highlights from the week in Psychiatric Times.

What is new in research on ADHD?

Updates from Day 2 at the National Academy of Sciences Conference on adult ADHD.

Check out these updates for the National Academy of Sciences Conference on adult ADHD, including new research, thoughtful discussions, and more!

Researchers performed a double-blind, placebo-controlled pilot study of solriamfetol.

From sleep disturbances in ADHD to psychotherapy for treatment-resistant depression, here are highlights from the week in Psychiatric Times.